Leading researchers will present their results at the 2021 edition of the International Liver Conference EASL™ and demonstrate the predictive value of the ‘Agile’ results obtained thanks to…

Leading researchers to present their findings at the 2021 edition of the EASL™ International Liver Conference and demonstrate the predictive value of ‘Agile’ results obtained using FibroScan from Echosens in patients with liver disease.

echoToday, the high-tech company behind the FibroScan product line announced that senior researchers will present results of studies supporting the added value of FibroScan in International Liver Conference (EASL) It was staged June 23-26, 2021. An area to be addressed is the ‘Agile’ score obtained by FibroScan, which makes it possible to easily detect cirrhosis and advanced fibrosis in patients with nonalcoholic fatty liver disease ( NASH).

The ‘Agile’ scores were generated from data from a large international group of patients and externally validated on two large patient groups – one in France and one in the US – to achieve this extraordinary level of sophistication,” said Dominique Legros, CEO of the group. Echosens.” These innovative results, obtained in a non-invasive manner, make it possible to reduce the number of false positives until then only diagnosed by pulsed elastic imaging with controlled vibration to measure the stiffness or elasticity of the liver (LSM by VCTE™), predicting complications In the coming years, identify patients likely to benefit from therapeutic treatments. ”

Currently available non-surgical tests, including FIB-4 and LSM by VCTE™, are very effective in ruling out cirrhosis and advanced fibrosis, but their ability to confirm them is moderate. Agile 3+ better identifies advanced fibrosis in patients with NASH and may reduce the need for liver biopsy in these patients. The ‘Agile 4’ score allows for better identification of cirrhotic patients and can reduce the need for liver biopsy for this diagnostic goal, while identifying patients likely to be tested for potential cancers and hepatocyte and esophageal varices.

READ  A cosmic web woven in the depths of the universe

Dr. Mazen Noureddine, program director focused on steatosis at Cedars-Sinai, who will deliver the presentation “Modeling Regional Differences vs. VCTE Investment in Nonalcoholic Fatty Liver (NAFLD) Patients in the United States” at the conference: For VCTE devices such as FibroScan is a financially viable solution to work against the epidemic of nonalcoholic fatty liver disease (NAFLD), as the South and Midwest are the regions likely to benefit the most, likely due to the high NHS prevalence associated with co-morbidities. relevance, as well as in terms of use and medical costs. ”

About Echosens

A pioneer in its field of activity, Echosens has significantly modified the practice of liver diagnostics thanks to FibroScan®The non-surgical solution to managing overall liver health. Fibroscan® Recognized worldwide and validated by over 2,500 peer-reviewed publications and over 70 international recommendations. Echo has marketed the FibroScan® in more than 100 countries, enabling millions of liver tests to be performed around the world. https://www.echosens.com/

In no way should the text of the press release resulting from the translation be considered official. The only original copy of the press release is the original language press version. The translation should always be compared to the source text, which will set a precedent.

Leave a Reply

Your email address will not be published. Required fields are marked *